Relation of serum lipids and lipoproteins with progression of CKD: The CRIC study

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 7, 2014, Pages 1190-1198

  Rahman, Mahboob ^a   Yang, Wei ^b   Akkina, Sanjeev ^c   Alper, Arnold ^d   Anderson, Amanda Hyre ^b   Appel, Lawrence J ^e   He, Jiang ^d   Raj, Dominic S ^f   Schelling, Jeffrey ^g   Strauss, Louise ^h   Teal, Valerie ^b   Rader, Daniel J ⁱ  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Centers for Clinical Epidemiology and Biostatistics   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d TULANE UNIVERSITY   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f GEORGE WASHINGTON UNIVERSITY   (United States)

^g METROHEALTH MEDICAL CENTER   (United States)

^h UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; PROSPECTIVE STUDY; PROTEINURIA; ULTRACENTRIFUGATION; BLOOD; COMPLICATION; HYPERLIPIDEMIAS; KIDNEY; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PATHOPHYSIOLOGY; PROTECTION; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; YOUNG ADULT;

ADULT; AGED; BIOMARKERS; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; KIDNEY; KIDNEY FAILURE, CHRONIC; LIPIDS; LIPOPROTEINS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTECTIVE FACTORS; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; YOUNG ADULT;

EID: 84906727532     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.09320913     Document Type: Article

References (37)

1. Kaysen GA: New insights into lipid metabolism in chronic kidney disease. J Ren Nutr 21: 120–123, 2011
2. Vaziri ND: Lipotoxicity and impaired high density lipoproteinmediated reverse cholesterol transport in chronic kidney disease. J Ren Nutr 20[Suppl]: S35–S43, 2010
3. Kasiske BL, O’Donnell MP, Cleary MP, Keane WF: Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 33: 667–672, 1988
4. Kasiske BL, O’Donnell MP, Cleary MP, Keane WF: Effects of reduced renal mass on tissue lipids and renal injury in hyperlipidemic rats. Kidney Int 35: 40–47, 1989
5. Kasiske BL, O’Donnell MP, Schmitz PG, Kim Y, Keane WF: Renal injury of diet-induced hypercholesterolemia in rats. Kidney Int 37: 880–891, 1990
6. Kasiske BL, O’Donnell MP, Keane WF: The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. Hypertension 19[Suppl]: I110–I115, 1992
7. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D: Predictors of new-onset kidney disease in a community-based population. JAMA 291: 844–850, 2004
8. Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent C, Buring JE, Gaziano JM: Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 14: 2084–2091, 2003
9. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ: Plasma lipids and risk of developing renal dysfunction: The Atherosclerosis Risk in Communities study. Kidney Int 58: 293–301, 2000
10. Hadjadj S, Duly-Bouhanick B, Bekherraz A, BrIdoux F, Gallois Y, Mauco G, Ebran J, Marre M: Serum triglycerides are a predictive factor for the development and the progression of renal and retinal complications in patients with type 1 diabetes. Diabetes Metab 30: 43–51, 2004
11. Chawla V, Greene T, Beck GJ, Kusek JW, Collins AJ, Sarnak MJ, Menon V: Hyperlipidemia and long-term outcomes in nondiabetic chronic kidney disease. Clin J AmSoc Nephrol 5: 1582–1587, 2010
12. Samuelsson O, Mulec H, Knight-Gibson C, Attman PO, Kron B, Larsson R, Weiss L, Wedel H, Alaupovic P: Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 12:1908–1915, 1997
13. Kaysen GA: Lipid and lipoprotein metabolism in chronic kidney disease. J Ren Nutr 19: 73–77, 2009
14. Kaysen GA: Disorders in high-density metabolism with insulin resistance and chronic kidney disease. J Ren Nutr 17: 4–8, 2007
15. Dalrymple LS, Kaysen GA: The effect of lipoproteins on the development and progression of renal disease. Am J Nephrol 28: 723–731, 2008
16. Navaneethan SD, Pansini F, Perkovic V, Manno C, Pellegrini F, Johnson DW, Craig JC, Strippoli GFM: HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev CD007784, 2009
17. Rahman M, Baimbridge C, Davis BR, Barzilay J, Basile JN, Henriquez MA, Huml A, Kopyt N, Louis GT, Pressel SL, Rosendorff C, Sastrasinh S, Stanford C; ALLHAT Collaborative Research Group: Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Kidney Dis 52: 412–424, 2008
18. Feldman HI, Appel LJ, Chertow GM, Cifelli D, Cizman B, Daugirdas J, Fink JC, Franklin-Becker ED, Go AS, Hamm LL, He J, Hostetter T, Hsu CY, Jamerson K, Joffe M, Kusek JW, Landis JR, Lash JP, Miller ER, Mohler ER 3rd, Muntner P, Ojo AO, Rahman M, Townsend RR, Wright JT; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators: The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and methods. J Am Soc Nephrol 14 [Suppl 2]: S148–S153, 2003
19. Lash JP, Go AS, Appel LJ, He J, Ojo A, Rahman M, Townsend RR, Xie D, Cifelli D, Cohan J, Fink JC, Fischer MJ, Gadegbeku C, Hamm LL, Kusek JW, Landis JR, Narva A, Robinson N, Teal V, Feldman HI; Chronic Renal Insufficiency Cohort (CRIC) Study Group: Chronic Renal Insufficiency Cohort (CRIC) Study: Baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol 4: 1302–1311, 2009
20. Joffe M, Hsu CY, Feldman HI, Weir M, Landis JR, Hamm LL; Chronic Renal Insufficiency Cohort (CRIC) Study Group: Variability of creatinine measurements in clinical laboratories: Results from the CRIC study. Am J Nephrol 31: 426–434, 2010
21. Anderson AH, Yang W, Hsu CY, Joffe MM, Leonard MB, Xie D, Chen J, Greene T, Jaar BG, Kao P, Kusek JW, Landis JR, Lash JP, Townsend RR, Weir MR, Feldman HI; CRIC Study Investigators: Estimating GFR among participants in the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 60: 250–261, 2012
22. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, Tracy RP, Powe NR, Klag MJ: Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 291: 451–459, 2004
23. Cox DR: Regression models and life-tables. J R Stat Soc B 34: 187–220, 2011
24. Laird NM, Ware JH: Random-effects models for longitudinal data. Biometrics 38: 963–974, 1982
25. Vaziri ND, Norris K: Lipid disorders and their relevance to outcomes in chronic kidney disease. Blood Purif 31: 189–196, 2011
26. Lee PH, Chang HY, Tung CW, Hsu YC, Lei CC, Chang HH, Yang HF, Lu LC, Jong MC, Chen CY, Fang KY, Chao YS, Shih YH, Lin CL: Hypertriglyceridemia:An independent risk factor of chronic kidney disease in Taiwanese adults. Am J Med Sci 338: 185–189, 2009
27. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R; SHARP Investigators: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomized placebo-controlled trial. Lancet 377: 2181–2192, 2011
28. Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, Rogers NL, Teschan PE: Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 51: 1908–1919, 1997
29. Li L, Astor BC, Lewis J, Hu B, Appel LJ, Lipkowitz MS, Toto RD, Wang X, Wright JT Jr, Greene TH: Longitudinal progression trajectory of GFR among patients with CKD. Am J Kidney Dis 59:504–512, 2012
30. Syrjänen J, Mustonen J, Pasternack A: Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 15: 34–42, 2000
31. Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG, Danesh J; Emerging Risk Factors Collaboration: Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302: 412–423, 2009
32. Kronenberg F: Epidemiology, pathophysiology and therapeutic implications of lipoprotein(a) in kidney disease. Expert Rev Cardiovasc Ther 2: 729–743, 2004
33. Sechi LA, Zingaro L, De Carli S, Sechi G, Catena C, Falleti E, Dell’Anna E, Bartoli E: Increased serum lipoprotein(a) levels in patients with early renal failure. Ann InternMed 129: 457–461, 1998
34. Uhlig K, Wang SR, Beck GJ, Kusek JW, Marcovina SM, Greene T, Levey AS, Sarnak MJ: Factors associated with lipoprotein(a) in chronic kidney disease. Am J Kidney Dis 45: 28–38, 2005
35. Song KH, Ko SH, Kim HW, Ahn YB, Lee JM, Son HS, Yoon KH, Cha BY, Lee KW, Son HY: Prospective study of lipoprotein(a) as a risk factor for deteriorating renal function in type 2 diabetic patients with overt proteinuria. Diabetes Care 28: 1718–1723, 2005
36. Al-Shahrouri HZ, Ramirez P, Fanti P, Abboud H, Lorenzo C, Haffner S: NMR identifies atherogenic lipoprotein abnormalities in early diabetic nephropathy that are unrecognized by conventional analysis. Clin Nephrol 73: 180–189, 2010
37. Ooi EM, Chan DT, Watts GF, Chan DC, Ng TW, Dogra GK, Irish AB, Barrett PH: Plasma apolipoprotein C-III metabolism in patientswith chronic kidney disease. J Lipid Res 52: 794–800, 2011